JP5735650B2 - Peg化エリスロポエチンを精製するための方法 - Google Patents
Peg化エリスロポエチンを精製するための方法 Download PDFInfo
- Publication number
- JP5735650B2 JP5735650B2 JP2013528645A JP2013528645A JP5735650B2 JP 5735650 B2 JP5735650 B2 JP 5735650B2 JP 2013528645 A JP2013528645 A JP 2013528645A JP 2013528645 A JP2013528645 A JP 2013528645A JP 5735650 B2 JP5735650 B2 JP 5735650B2
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- solution
- ethylene glycol
- poly
- conductivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 55
- 108010048732 pegylated erythropoietin Proteins 0.000 title description 30
- 229920001223 polyethylene glycol Polymers 0.000 claims description 95
- 102000003951 Erythropoietin Human genes 0.000 claims description 87
- 108090000394 Erythropoietin Proteins 0.000 claims description 87
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 86
- 229940105423 erythropoietin Drugs 0.000 claims description 85
- 239000000463 material Substances 0.000 claims description 59
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 238000004587 chromatography analysis Methods 0.000 claims description 30
- 239000012506 Sephacryl® Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 13
- 102000044890 human EPO Human genes 0.000 claims description 13
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 description 69
- 238000010828 elution Methods 0.000 description 23
- 239000000126 substance Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 239000000872 buffer Substances 0.000 description 16
- 238000000746 purification Methods 0.000 description 14
- 239000000562 conjugate Substances 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 230000006320 pegylation Effects 0.000 description 11
- 230000004927 fusion Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 9
- 230000001143 conditioned effect Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- -1 sulfopropyl Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 0 C*[C@@](CNCO)[C@@](C)OCCO* Chemical compound C*[C@@](CNCO)[C@@](C)OCCO* 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000012500 ion exchange media Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000012437 strong cation exchange chromatography Methods 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/26—Cation exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Description
本明細書において、反応副生成物又は未反応の出発物質からのエリスロポエチン及び単一のポリ(エチレングリコール)残基を含むタンパク質コンジュゲートの陽イオン交換クロマトグラフィー法による精製方法を記載する。陽イオン交換クロマトグラフィー材料SP Sephacryl S 500 HR及び線形勾配溶出を、規定の伝導率の緩衝液を事前に適用したカラムに用いることによって、エリスロポエチン及び単一のポリ(エチレングリコール)残基を含むコンジュゲートタンパク質を、単一工程において、高純度及び高収率で得ることができることが見出された。
a)約21mS/cmの伝導率を有する溶液を、SP Sephacryl S 500 HRクロマトグラフィー材料を含むクロマトグラフィーカラムに適用する工程、
b)遊離エリスロポエチンとエリスロポエチン分子当たり1つ又は複数のポリ(エチレングリコール)残基を有するエリスロポエチン及びポリ(エチレングリコール)の融合タンパク質との混合物を含む溶液を、a)のカラムに適用する工程、
c)約21mS/cmの伝導率を有する溶液をカラムに適用して、それによって、2つ以上のポリ(エチレングリコール)残基を含む融合タンパク質を回収する工程、
d)少なくとも60mS/cmの最終値まで連続的及び線形的に増加する伝導率を有する溶液をカラムに適用して、それによって、エリスロポエチン及び単一のポリ(エチレングリコール)残基を含む融合タンパク質と遊離エリスロポエチンとを別々に回収する工程、これにより、エリスロポエチン及び単一のポリ(エチレングリコール)残基を含む融合タンパク質が最初に得られる、
を含む方法を記載する。
本明細書において、勾配溶出法を用いた1つのエリスロポエチン分子及び1つのポリ(エチレングリコール)残基を含むタンパク質を精製するための方法を記載する。ここで、勾配は、SP Sephacryl S 500 HRカラムでの線形伝導率勾配であり、規定の伝導率を有する溶液を、タンパク質を含む溶液の適用の前にクロマトグラフィーカラムに適用する。
a)20kDa〜40kDaの分子量の活性化ポリ(エチレングリコール)エステルを使用して、エリスロポエチンとポリ(エチレングリコール)をコンジュゲーションする工程、
b)工程a)で得られたコンジュゲートを、約21mS/cmの伝導率を有する溶液が適用されたSP Sephacryl S 500 HRクロマトグラフィー材料に適用する工程、
c)線形伝導率勾配溶出により、実質的に均質の形態の1つのエリスロポエチン分子及び単一のポリ(エチレングリコール)残基(モノPEG化エリスロポエチン)を含むタンパク質を回収して、それによって、エリスロポエチン及び単一のポリ(エチレングリコール)残基を含むタンパク質コンジュゲートを生成する工程
を含む方法を提供する。
(1)疎水性:ノルロイシン、Met、Ala、Val、Leu、Ile;
(2)中性親水性:Cys、Ser、Thr、Asn、Gln;
(3)酸性:Asp、Glu;
(4)塩基性:His、Lys、Arg;
(5)鎖配向に影響を及ぼす残基:Gly、Pro;
(6)芳香族性:Trp、Tyr、Phe
(式中、R及びmは、上記で定義されるとおりである)
一実施態様においては、PEG種は、メトキシポリ(エチレングリコール)酪酸のN−ヒドロキシスクシンイミジルエステルである。用語「アルコキシ」は、アルキルエーテル基を指す(ここで、用語「アルキル」は、最大4個の炭素原子を含有する直鎖又は分岐鎖アルキル基、例えば、メトキシ、エトキシ、n−プロポキシなどであり、好ましくは、メトキシを意味する)。
a)約21mS/cmの伝導率を有する溶液を、SP Sephacryl S 500 HRクロマトグラフィー材料を含むクロマトグラフィーカラムに適用する工程、
b)遊離エリスロポエチンとエリスロポエチン分子当たり1つ又は複数のポリ(エチレングリコール)残基を有するエリスロポエチン及びポリ(エチレングリコール)のタンパク質コンジュゲートとの混合物を含む溶液を、a)のカラムに適用する工程、
c)約21mS/cmの伝導率を有する溶液をカラムに適用して、それによって、遊離ポリ(エチレングリコール)、及び2つ以上のポリ(エチレングリコール)残基を含むタンパク質を回収する工程、
d)約62.5mS/cmの最終値まで連続的及び線形的に増加する伝導率を有する溶液をカラムに適用して、それによって、エリスロポエチン及び単一のポリ(エチレングリコール)残基を含むタンパク質と遊離エリスロポエチンとを別々に回収する工程(ここで、エリスロポエチン及び単一のポリ(エチレングリコール)残基を含むタンパク質が最初に得られる)
を含む。
配列番号:01 ヒトエリスロポエチンのアミノ酸配列
配列番号:02 ヒトエリスロポエチンのアミノ酸配列
分析サイズ排除クロマトグラフィー:
樹脂:TSK 3000(Tosohaas)
カラム:300×7.8mm
流速:0.5ml/分
溶出溶液:250mM塩化カリウムを含有する200mMリン酸カリウム、pH7.0に調整
波長:220nm
樹脂:SP Sephacryl S 500 HR
ベッド容量:2.5ml
試料負荷:mg/ml樹脂−可変(下記実施例を参照)
流速:0.5ml/分
溶液:A:100mMリン酸カリウム、pH3.0に調整
B:100mMリン酸カリウム、1000mM塩化ナトリウム、pH3.0に調整
適用溶液:88%A及び12%B
洗浄溶液:88%A及び12%B
洗浄容量:20ml(8カラム容量(CV))
線形勾配溶出溶液:100%B
線形勾配:25ml(10カラム容量)〜100%B以内
波長:254nm、280nm
約21mS/cmの伝導率を有する溶液で条件付けしたSP-Sephacrylクロマトグラフィー材料を用いた、PEG化エリスロポエチン調製物のクロマトグラフィー
PEG化エリスロポエチンのクロマトグラフィーを材料及び方法の部に記載のようにして実施した。
約29mS/cmの伝導率を有する溶液で条件付けしたSP-Sephacrylクロマトグラフィー材料を用いた、PEG化エリスロポエチン調製物のクロマトグラフィー
PEG化エリスロポエチンのクロマトグラフィーを材料及び方法の部に記載のようにして、下記の異なるパラメーターを用いて実施した:
適用溶液:80%A及び20%B
洗浄溶液:80%A及び20%B
洗浄容量:20ml(8カラム容量(CV))
線形勾配溶出緩衝液:100%B
線形勾配:25ml(10カラム容量)〜50%B以内
約21mS/cmの伝導率を有する溶液で条件付けしたSP-Sephacrylクロマトグラフィー材料及び37mS/cmの伝導率を有する溶液での段階溶出を用いた、PEG化エリスロポエチン調製物のクロマトグラフィー
PEG化エリスロポエチンのクロマトグラフィーを材料及び方法に記載のようにして実施した。
約21mS/cmの伝導率を有する溶液で条件付けしたSP-Sephacrylクロマトグラフィー材料及び20mS/cmの伝導率に調整した試料を用いた、PEG化エリスロポエチン調製物のクロマトグラフィー
PEG化エリスロポエチンのクロマトグラフィーを材料及び方法に記載のようにして実施した。
Claims (8)
- エリスロポエチン及び単一のポリ(エチレングリコール)残基を含むタンパク質を得るための方法であって、以下の工程:
a)エリスロポエチンとエリスロポエチン分子当たり1つ又は複数のポリ(エチレングリコール)残基を有するエリスロポエチン及びポリ(エチレングリコール)のコンジュゲートとの混合物を含む溶液を、21mS/cmの伝導率を有する溶液が適用されたSP Sephacryl S 500 HR(商標)クロマトグラフィー材料を含むカラムに適用する工程、
b)21mS/cmの伝導率を有する溶液をカラムに適用して、それによって、遊離ポリ(エチレングリコール)、及び2つ以上のポリ(エチレングリコール)残基を含むタンパク質を回収する工程、
c)62.5mS/cmの最終値まで線形的に増加する伝導率を有する溶液をカラムに適用して、それによって、エリスロポエチン及び単一のポリ(エチレングリコール)残基を含むタンパク質とエリスロポエチンを別々に回収する工程、これにより、エリスロポエチン及び単一のポリ(エチレングリコール)残基を含むタンパク質が最初に回収される工程、
を含み、
21mS/cmの伝導率を有する溶液が、pH2.5〜pH3.5のpH値を有する溶液であることを特徴とする、
方法。 - 21mS/cmの伝導率を有する溶液が、pH2.5〜pH3.5のpH値を有するリン酸緩衝液であることを特徴とする、請求項1に記載の方法。
- エリスロポエチンとエリスロポエチン分子当たり1つ又は複数のポリ(エチレングリコール)残基を有するエリスロポエチン及びポリ(エチレングリコール)のコンジュゲートとの混合物を含む溶液を、21mS/cmの伝導率に調整しないことを特徴とする、請求項1または2に記載の方法。
- 線形的に増加する伝導率を有する溶液が、線形的に増加する塩化ナトリウム濃度を有する溶液であることを特徴とする、請求項1〜3のいずれか一項に記載の方法。
- 線形的に増加する伝導率を有する溶液が、pH2.3〜pH3.5のpH値を有することを特徴とする、請求項1〜4のいずれか一項に記載の方法。
- エリスロポエチンが、ヒトエリスロポエチンであることを特徴とする、請求項1〜5のいずれか一項に記載の方法。
- ヒトエリスロポエチンが、配列番号:01又は配列番号:02のアミノ酸配列を有することを特徴とする、請求項6に記載の方法。
- 単一のポリ(エチレングリコール)残基が、20kDa〜40kDaの分子量を有することを特徴とする、請求項1〜7のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10176616.0 | 2010-09-14 | ||
EP10176616 | 2010-09-14 | ||
PCT/EP2011/065888 WO2012035037A1 (en) | 2010-09-14 | 2011-09-13 | Method for purifying pegylated erythropoietin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013537208A JP2013537208A (ja) | 2013-09-30 |
JP5735650B2 true JP5735650B2 (ja) | 2015-06-17 |
Family
ID=43385653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013528645A Active JP5735650B2 (ja) | 2010-09-14 | 2011-09-13 | Peg化エリスロポエチンを精製するための方法 |
Country Status (15)
Country | Link |
---|---|
US (4) | US20120197007A1 (ja) |
EP (1) | EP2616101B1 (ja) |
JP (1) | JP5735650B2 (ja) |
KR (1) | KR101578586B1 (ja) |
CN (1) | CN103118708B (ja) |
BR (1) | BR112013005890B1 (ja) |
CA (1) | CA2808748C (ja) |
DK (1) | DK2616101T3 (ja) |
ES (1) | ES2500048T3 (ja) |
HK (1) | HK1181661A1 (ja) |
MX (1) | MX342444B (ja) |
PL (1) | PL2616101T3 (ja) |
RU (1) | RU2566267C2 (ja) |
SI (1) | SI2616101T1 (ja) |
WO (1) | WO2012035037A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102816227A (zh) * | 2012-08-30 | 2012-12-12 | 深圳赛保尔生物药业有限公司 | 回收促红细胞生成素的方法 |
DE102016210647B3 (de) | 2016-06-15 | 2017-09-14 | Schaeffler Technologies AG & Co. KG | Keilkupplung-Synchronisation |
PL3484911T3 (pl) * | 2016-07-15 | 2021-03-08 | F. Hoffmann-La Roche Ag | Sposób oczyszczania PEGylowanej erytropoetyny |
US10695402B2 (en) | 2017-03-16 | 2020-06-30 | University Of Rochester | Erythropoietin for gastrointestinal dysfunction |
SI3731873T1 (sl) * | 2017-12-29 | 2022-05-31 | F. Hoffmann-La Roche Ag | Postopek za zagotavljanje sestavka PEGiliranih beljakovin |
JP7137625B2 (ja) | 2017-12-29 | 2022-09-14 | エフ.ホフマン-ラ ロシュ アーゲー | Peg化タンパク質組成物を提供するための方法 |
US11518781B2 (en) | 2017-12-29 | 2022-12-06 | Hoffmann-La Roche Inc. | Process for providing PEGylated protein composition |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118796A (en) | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
AU635844B2 (en) | 1989-11-06 | 1993-04-01 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
DE69034135T3 (de) | 1989-12-22 | 2012-08-23 | Laboratoires Serono S.A. | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
DE4118912C1 (ja) | 1991-06-08 | 1992-07-02 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
AU673190B2 (en) | 1992-07-13 | 1996-10-31 | Bionebraska, Inc. | Method for modification of recombinant polypeptides |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
PT1157037E (pt) | 1999-01-29 | 2003-12-31 | Hoffmann La Roche | Conjugados de gcsf |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
WO2001058957A2 (en) | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
US20050100991A1 (en) | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2003265994B2 (en) * | 2002-09-11 | 2010-04-01 | Genentech, Inc. | Protein purification |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
US20050008649A1 (en) | 2003-06-02 | 2005-01-13 | University Of Miami | Chimeric molecules and methods of use |
SE0401951D0 (sv) | 2004-07-29 | 2004-07-29 | Amersham Biosciences Ab | Chromatography method |
KR20070100299A (ko) | 2004-12-22 | 2007-10-10 | 암브룩스, 인코포레이티드 | 재조합 인간 성장 호르몬의 발현 및 정제 방법 |
WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
AR067536A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
US20120172299A1 (en) | 2008-09-23 | 2012-07-05 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
MX2011008963A (es) | 2009-03-05 | 2012-02-01 | Ascendis Pharma As | Profarmacos portadores de interferon alfa. |
-
2011
- 2011-09-13 CA CA2808748A patent/CA2808748C/en active Active
- 2011-09-13 BR BR112013005890-0A patent/BR112013005890B1/pt active IP Right Grant
- 2011-09-13 SI SI201130253T patent/SI2616101T1/sl unknown
- 2011-09-13 ES ES11754693.7T patent/ES2500048T3/es active Active
- 2011-09-13 JP JP2013528645A patent/JP5735650B2/ja active Active
- 2011-09-13 DK DK11754693.7T patent/DK2616101T3/da active
- 2011-09-13 PL PL11754693T patent/PL2616101T3/pl unknown
- 2011-09-13 MX MX2013002554A patent/MX342444B/es active IP Right Grant
- 2011-09-13 CN CN201180044060.8A patent/CN103118708B/zh active Active
- 2011-09-13 WO PCT/EP2011/065888 patent/WO2012035037A1/en active Application Filing
- 2011-09-13 EP EP11754693.7A patent/EP2616101B1/en active Active
- 2011-09-13 RU RU2013113724/15A patent/RU2566267C2/ru active
- 2011-09-13 KR KR1020137009524A patent/KR101578586B1/ko active IP Right Grant
- 2011-09-14 US US13/232,628 patent/US20120197007A1/en not_active Abandoned
-
2013
- 2013-08-02 HK HK13109018.4A patent/HK1181661A1/xx unknown
- 2013-11-26 US US14/090,927 patent/US20140163207A1/en not_active Abandoned
-
2016
- 2016-02-19 US US15/048,689 patent/US10273277B2/en active Active
-
2020
- 2020-09-17 US US17/024,477 patent/US20210094993A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170008941A1 (en) | 2017-01-12 |
EP2616101B1 (en) | 2014-07-09 |
MX2013002554A (es) | 2013-05-28 |
ES2500048T3 (es) | 2014-09-29 |
JP2013537208A (ja) | 2013-09-30 |
RU2566267C2 (ru) | 2015-10-20 |
US20140163207A1 (en) | 2014-06-12 |
KR101578586B1 (ko) | 2015-12-17 |
CA2808748A1 (en) | 2012-03-22 |
EP2616101A1 (en) | 2013-07-24 |
HK1181661A1 (en) | 2013-11-15 |
US20120197007A1 (en) | 2012-08-02 |
US10273277B2 (en) | 2019-04-30 |
SI2616101T1 (sl) | 2014-10-30 |
DK2616101T3 (da) | 2014-08-04 |
MX342444B (es) | 2016-09-29 |
CN103118708B (zh) | 2015-08-26 |
BR112013005890B1 (pt) | 2022-02-08 |
RU2013113724A (ru) | 2014-10-20 |
PL2616101T3 (pl) | 2015-01-30 |
BR112013005890A2 (pt) | 2020-04-14 |
KR20130073964A (ko) | 2013-07-03 |
CA2808748C (en) | 2018-09-11 |
US20210094993A1 (en) | 2021-04-01 |
WO2012035037A1 (en) | 2012-03-22 |
CN103118708A (zh) | 2013-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5735650B2 (ja) | Peg化エリスロポエチンを精製するための方法 | |
JP5814978B2 (ja) | ペグ化ポリペプチドの精製 | |
JP5025796B2 (ja) | クロマトグラフィー方法 | |
JP7177035B2 (ja) | Peg化エリスロポエチンを精製するための方法 | |
AU2012258485A1 (en) | Chromatographic methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141009 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150324 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150416 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5735650 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |